Revive Therapeutics' experimental COVID treatment fails in late-stage study

Revive Therapeutics' experimental COVID treatment fails in late-stage study Canada-based Revive Therapeutics said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study. Reuters Reuters

...

The company was evaluating the safety and efficacy of its oral treatment, bucillamine, in the study which enrolled 713 patients with mild to moderate COVID-19.

...